Worldquant Millennium Advisors LLC Decreases Stake in United Therapeutics Co. (NASDAQ:UTHR)

Worldquant Millennium Advisors LLC decreased its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 81.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,688 shares of the biotechnology company's stock after selling 34,562 shares during the period. Worldquant Millennium Advisors LLC's holdings in United Therapeutics were worth $2,755,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of UTHR. ClariVest Asset Management LLC lifted its stake in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC bought a new position in shares of United Therapeutics in the 2nd quarter worth approximately $30,000. Innealta Capital LLC bought a new position in shares of United Therapeutics in the 2nd quarter worth approximately $33,000. USA Financial Formulas bought a new position in shares of United Therapeutics in the 3rd quarter worth approximately $33,000. Finally, Brooklyn Investment Group bought a new position in shares of United Therapeutics in the 3rd quarter worth approximately $33,000. Institutional investors own 94.08% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. The Goldman Sachs Group increased their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a report on Friday, November 1st. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH raised their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Finally, Argus raised their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $370.86.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded down $2.67 during mid-day trading on Monday, reaching $367.00. 246,383 shares of the company's stock were exchanged, compared to its average volume of 451,021. The firm has a market capitalization of $16.39 billion, a price-to-earnings ratio of 16.23, a PEG ratio of 1.07 and a beta of 0.55. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82. The company's 50-day moving average is $369.14 and its 200-day moving average is $339.50.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million during the quarter, compared to analysts' expectations of $722.62 million. During the same period last year, the business posted $5.38 EPS. United Therapeutics's revenue for the quarter was up 22.9% on a year-over-year basis. As a group, equities analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insider Activity

In other United Therapeutics news, Director Christopher Causey sold 510 shares of United Therapeutics stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the transaction, the director now owns 3,675 shares of the company's stock, valued at $1,384,115.25. The trade was a 12.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO James Edgemond sold 7,792 shares of United Therapeutics stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $358.62, for a total value of $2,794,367.04. Following the transaction, the chief financial officer now directly owns 4,802 shares in the company, valued at approximately $1,722,093.24. This trade represents a 61.87 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 119,340 shares of company stock worth $44,765,530. 11.90% of the stock is currently owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.